Estimated Glucose Disposal Rate and Risk of Vascular Events and Death in Type 2 Diabetes in the ADVANCE Study
Primary result · Composite major macrovascular and microvascular eventResult — go to the resultHazard ratio 0.72 95% CI 0.62–0.84Authors' conclusion
These findings highlight the value of eGDR as a prognostic marker for T2D. Intensive glucose- and BP-lowering treatments remain beneficial regardless of insulin resistance status.
Study context
- Population
- Participants with T2D from 20 countries in the ADVANCE trial; Estimated glucose disposal rate (eGDR) derived from waist circumference, hypertension status and HbA1ceGDR in 11,081
- Participants
- 11,140 participants
- Comparison
- Highest vs lowest quarter of eGDR
- Primary endpoint
- Composite:
- Major macrovascular
- Microvascular event
- Follow-up
- Median 5 years
Methodological details20 countries, multivariable Cox models
- 20 countries
- Multivariable Cox models
Primary result
As reported in the abstract
median 5 years
Hazard ratio
0.72
95% CI 0.62–0.84
Highest quarter of eGDRvs Lowest quarter of eGDR
HR 0.72 (95% CI 0.62–0.84)
- Major macrovascular or microvascular event, all participants
- 2117 (19.1%)
Further findings
| Outcome | HR (95% CI) | |
|---|---|---|
| Major macrovascular events | 0.68 (0.55–0.85) | |
| Major microvascular events | 0.78 (0.63–0.96) | |
| All-cause mortality | 0.69 (0.55–0.86) | |
| CV mortality | 0.62 (0.45–0.85) | |
| 0.512Hazard ratio (log scale) |
Effect modification by eGDR quarter
- No significant effect modification across eGDR quarters for efficacy or safety of intensive glucose control (vs standard) or blood pressure (BP)-lowering (vs placebo)
Original publication
Estimated Glucose Disposal Rate and Risk of Vascular Events and Death in Type 2 Diabetes in the ADVANCE Study. Diabetes Obes Metab. Published 9 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →